Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow PHAR
Pharming Group N.V. Sponsored ADR (PHAR) EV/Sales
As of 16 October 2026, Pharming Group N.V. Sponsored ADR (PHAR) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from −5.2× (September 2023) to 52.0× (December 2020); the current reading is higher than 5% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.0× | 51.89% |
| FY2024 | 2.0× | (28.37%) |
| FY2023 | 2.8× | (15.75%) |
| FY2022 | 3.3× | (88.74%) |
| FY2021 | 29.3× | (34.68%) |
| FY2020 | 44.8× | (13.89%) |
| FY2019 | 52.0× | 0.00% |
| FY2018 | 52.0× | 0.00% |
| FY2017 | 52.0× | 0.00% |
| FY2016 | 52.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.9× | (41.22%) |
| Mar 2026 | 3.2× | 4.65% |
| Dec 2025 | 3.0× | 18.85% |
| Sep 2025 | 2.5× | 28.78% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANNX Annexon, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR | 1.2× |
| MDXG MiMedx Group, Inc compare | 1.5× |
| GYRE Gyre Therapeutics, Inc. compare | 4.7× |
| OABI OmniAb, Inc. compare | 14.0× |
| PRME Prime Medicine, Inc. compare | 128× |
| DSGN Design Therapeutics, Inc. compare | 1,934× |
| CADL Candel Therapeutics, Inc. compare | 3,661× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)